00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:56 , Sep 14, 2017 |  BC Extra  |  Financial News

Aldeyra stock surge continues

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) jumped $4.45 (70%) to $10.80 on Thursday as momentum continued following a Phase IIa data readout on Tuesday showing that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry...
20:30 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

Aldeyra planning Phase III trial of ADX-102 despite Phase IIb miss in allergic conjunctivitis

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported data from a Phase IIb trial in 154 patients with acute allergic conjunctivitis, including seasonal and perennial allergies, showing that 0.1% and 0.5% doses of ADX-102 ophthalmic drops both missed...
00:26 , May 3, 2017 |  BC Week In Review  |  Clinical News

Aldeyra starts Ph III of ADX-102 for non-infectious anterior uveitis

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) began a Phase III trial to evaluate 0.5% ADX-102 ophthalmic solution for 4 weeks in about 100 patients with non-infectious anterior uveitis. The primary endpoint of the double-blind, vehicle-controlled, U.S. trial...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

Topical NS2: Phase II data

A double-blind, U.S. Phase II trial in 12 Sjogren-Larsson syndrome patients with moderate to severe ichthyosis showed that once-daily 1% topical NS2 administered on a 4x10 inch area of skin for 2 months significantly improved...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Topical NS2: Phase II started

Aldeyra began a double-blind, vehicle-controlled, U.S. Phase II trial to evaluate once-daily topical NS2 1% in about 12 patients. Aldeyra Therapeutics Inc. (NASDAQ:ALDX), Burlington, Mass.   Product: Topical NS2   Business: Dermatology   Molecular target: NA   Description:...